<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Pharmacol</journal-id><journal-id journal-id-type="publisher-id">IJPharm</journal-id><journal-title-group><journal-title>Indian Journal of Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0253-7613</issn><issn pub-type="epub">1998-3751</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24987174</article-id><article-id pub-id-type="pmc">4071704</article-id><article-id pub-id-type="publisher-id">IJPharm-46-281</article-id><article-id pub-id-type="doi">10.4103/0253-7613.132158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effect of preoperative oral sildenafil on severe pulmonary artery hypertension in patients undergoing mitral valve replacement</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gandhi</surname><given-names>Hemang</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Bipin</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Ramesh</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Toshani</surname><given-names>Rajesh</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Pujara</surname><given-names>Jigisha</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kothari</surname><given-names>Jignesh</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Shastri</surname><given-names>Naman</given-names></name><xref ref-type="aff" rid="aff2">1</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1">Department of Cardiac Anesthesia, Uttambhai Nathalal Mehta Institute of Cardiology and Research Center, Sir Byramjee Jeejeebhoy Medical College, Civil Hospital, Asarwa, Ahmadabad, Gujarat, India</aff><aff id="aff2"><label>1</label>Department of Cardio Vascular Thoracic Surgery, Uttambhai Nathalal Mehta Institute of Cardiology and Research Center, Sir Byramjee Jeejeebhoy Medical College, Civil Hospital, Asarwa, Ahmadabad, Gujarat, India</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr. Naman Shastri, E-mail: <email xlink:href="nashastri@gmail.com">nashastri@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>May-Jun</season><year>2014</year></pub-date><volume>46</volume><issue>3</issue><fpage>281</fpage><lpage>285</lpage><history><date date-type="received"><day>07</day><month>8</month><year>2013</year></date><date date-type="rev-recd"><day>27</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Pharmacology</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Aim:</title><p>Long standing mitral valve disease is usually associated with severe pulmonary hypertension. Perioperative pulmonary hypertension is a risk factor for right ventricular (RV) failure and a cause for morbidity and mortality in patients undergoing mitral valve replacement. Phosphodiesterase 5 inhibitor-sildenafil citrate is widely used to treat primary pulmonary hypertension. There is a lack of evidence of effects of oral sildenafil on secondary pulmonary hypertension due to mitral valve disease. The study aims to assess the effectiveness of preoperative oral sildenafil on severe pulmonary hypertension and incidence of RV failure in patients undergoing mitral valve replacement surgery.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>A total of 40 patients scheduled for mitral valve replacement with severe pulmonary hypertension (RV systolic pressure (RVSP) &#x02265;60 mmHg) on preoperative transthoracic echo were randomly treated with oral sildenafil 25 mg (<italic>N</italic> = 20) or placebo (<italic>N</italic> = 20) eight hourly for 24 h before surgery. Hemodynamic variables were measured 20 min after insertion of pulmonary artery catheter (PAC) under anesthesia (T1), 20 min at weaning from cardiopulmonary bypass (CPB) (T2) and after 1,2, and 6 h (T3, T4, T5, respectively) during the postoperative period.</p></sec><sec id="st3"><title>Results:</title><p>Systolic and mean pulmonary artery pressure (MPAP) and pulmonary vascular resistance index (PVRI) were significantly lower (<italic>P</italic> &#x0003c; 0.0001) in sildenafil group at all times. Ventilation time and postoperative recovery room stay were significantly lower (<italic>P</italic> &#x0003c; 0.001) in sildenafil group.</p></sec><sec id="st4"><title>Conclusion:</title><p>Sildenafil produces significant pulmonary vasodilatory effect as compared with placebo in mitral valve replacement patients with severe pulmonary hypertension. It also reduces ventilation time and intensive care unit (ICU) stay time as compared with placebo. It is concluded that sildenafil is effective in reducing pulmonary hypertension when administered preoperatively in patients with severe pulmonary hypertension undergoing mitral valve replacement surgery.</p></sec></abstract><kwd-group><title>KEY WORDS</title><kwd>Mitral valve disease</kwd><kwd>oral sildenafil</kwd><kwd>phosphodiesterase 5</kwd><kwd>phosphodiesterase 5 inhibitor</kwd><kwd>pulmonary hypertension</kwd><kwd>right ventricular failureEctua vigna Sim terurs</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>Mitral valve disease with pulmonary arterial hypertension (PAH) is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular (RV) failure and mortality.[<xref rid="ref1" ref-type="bibr">1</xref>] Prognosis of patients with severe PAH is poor, and treatment options are limited.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>] The goal of long-term therapy is to reduce pulmonary vasoconstriction, cause regression of vascular remodeling, and prevent thrombosis.[<xref rid="ref4" ref-type="bibr">4</xref>]</p><p>Pulmonary vascular resistance can be lowered by enhancing cyclic adenosine monophosphate (cAMP) using &#x003b2;-agonist or with the phosphodiesterase type III inhibitor, milrinone.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>] Vascular resistance can also be lowered with nitroso vasodilators (nitroglycerine (GTN), sodium nitroprusside, and inhaled nitric oxide). Although inhaled nitric oxide is extremely efficacious, its use is complicated by the requirement for an inhaled delivery system and rebound pulmonary hypertension upon its withdrawal.[<xref rid="ref7" ref-type="bibr">7</xref>]</p><p>Oral sildenafil phosphodiesterase type 5 (PDE5) inhibitor increases cyclic guanosine monophosphate (cGMP) levels and has been shown to be effective for primary pulmonary hypertension.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>] It has been shown that sildenafil can be used to manage secondary pulmonary hypertension in perioperative period in patients undergoing cardiac surgeries.[<xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref>]</p><p>This prospective double-blind randomized control study was planned to evaluate the efficacy of oral sildenafil preoperatively in patients with severe pulmonary hypertension undergoing mitral valve replacement surgeries.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><p>The patients were enrolled for the study after approval from Institutional Ethics Committee after obtaining written consent. A total of 40 patients who were scheduled for mitral valve replacement surgery with severe PAH, RV systolic pressure (RVSP) &#x02265;50mmHg, as measured by preoperative transthoracic echocardiography, were included in the study. The patients were randomly allocated to either sildenafil (in routine hospital supply) or placebo (multivitamin tablets similar in appearance to sildenafil were used in placebo group, as no other effective oral alternative is available to treat PAH) using a computerized randomization table.</p><p>Patients with associated cardiac disease (coronary artery occlusive disease, aortic valve disease, tricuspid regurgitation requiring tricuspid repair, and left ventricular systolic dysfunction ejection fraction &#x0003c;50%), previous cardiac operation, lung disease, liver disease, and renal disease were excluded.</p><p>Patients in group S (sildenafil, in routine hospital supply) and group C (control group) were administered oral sildenafil 25 mg (Penegra, Zydus Healthcare, India) three times a day in 24 h preoperative period and placebo in the same fashion, respectively. Nursing staff who were administering the drugs to the patients were blinded during the study. All the patients were administered tablet alprazolam 0.25 mg and tablet pantoprazole 40 mg the night before surgery.</p><p>On the day of surgery after arrival to preparation room, patients received 4-5 l of oxygen with mask. Vital parameters were monitored with ECG (electrocardiogram), NIBP (non-invasive blood pressure), and pulse oximeter. After infiltration of local anesthesia (2% lidocaine), a peripheral venous cannula (16 or 18 G) and 20 G arterial cannula in the radial artery of nondominant hand were inserted. Injection clonidine 1 &#x003bc;g/kg and injection midazolam 0.03 mg/kg intravenously were administered 20 min before surgery as a premedication in all patients. &#x0200a; Anesthesia was induced with injection midazolam (0.1 mg/kg), fentanyl (7-10 &#x003bc;g/kg), and injection vecuronium (0.08-0.12 mg/kg) and maintained with intermittent bolus doses of fentanyl (2 &#x003bc;g/kg) and vecuronium (0.04 mg/kg) with sevoflurane (1-2%). After induction of anesthesia, the lungs were ventilated with tidal volume of 8 ml/kg at a rate of 12 breaths/min in 50% oxygen-air mixture. Positive end-expiratory pressure was not applied. After that, ventilatory parameters were adjusted to maintain PaO<sub>2</sub> between 150-250 mmHg, PaCO2 between 33-38 mmHg, and pH 7.35-7.45.</p><p>After induction of anesthesia and under all aseptic and antiseptic precautions, pulmonary artery catheter (PAC) (Edwards Lifescience, Irvine, CA, USA) was inserted in the right internal jugular vein to monitor pulmonary artery pressure, pulmonary capillary wedge pressure (PCWP) and cardiac indices (CIs), &#x0200a; SVRI (systemic vascular resistance index), and PVRI (pulmonary vascular resistance index). A temperature probe was inserted into nasopharynx for monitoring of body temperature.</p><p>CPB (cardio pulmonary bypass) was performed with Stockert pump (Germany), using membrane oxygenator with standard institutional protocol. During weaning from CPB, GTN and dobutamine (5-10 &#x003bc;g/kg/min) was administered in all patients after achieving body temperature greater than 36&#x000b0;C and normalizing acid-base and electrolyte balance. After 10 min of weaning from CPB, inotropes were titrated according to MAP (mean arterial pressure) and&#x0200a; SPAP (systolic pulmonary artery pressure). The number of patients requiring inotropes was recorded.</p><sec id="sec2-1"><title/><sec id="sec3-1"><title>Data Collection and Analysis</title><p>Hemodynamic variables were measured 20 min after insertion of PAC under anesthesia (T1), 20 min after weaning from CPB (T2), 1, 2, and 6 h after transferring the patient to postoperative recovery period (T3, T4, T5). Heart rate (HR), MAP, systolic pulmonary arterial pressure (SPAP), mean pulmonary artery pressure (MPAP), PCWP, cardiac index (CI), systolic vascular resistance index (SVRI), and PVRI were measured at each interval. The statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) version 20.0. The values were expressed as mean &#x000b1; standard deviation (SD). Chi-square test and unpaired &#x0201c;<italic>t</italic>&#x0201d; test were used to calculate <italic>P</italic> values. A value of <italic>P</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec></sec><sec sec-type="results" id="sec1-3"><title>Results</title><p>A total of 40 patients were included in the study, 20 patients in each group. Demographic characteristics were similar in both groups. Other parameters like preoperative RVSP, CPB time, and cross-clamp time were similar in both groups (<italic>P</italic> = 0.936, <italic>P</italic> = 0.932, <italic>P</italic> = 0.902, respectively) [<xref ref-type="table" rid="T1">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of patients with mitral valve disease and pulmonary hypertension treated with sildenafil versus placebo</p></caption><graphic xlink:href="IJPharm-46-281-g001"/></table-wrap><p>Hemodynamic parameters, i. e. HR, MAP, and PCWP were similar in both groups after induction, after weaning from CPB, and in the postoperative period [<xref ref-type="table" rid="T2">Table 2</xref>]. SPAP and MPAP were significantly lower (<italic>P</italic> &#x0003c; 0.0001) during T1-T5 times in sildenafil group as compared with the control group [<xref ref-type="table" rid="T2">Table 2</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Hemodynamic parameters during mitral valve replacement surgery in sildenafil versus control groups</p></caption><graphic xlink:href="IJPharm-46-281-g002"/></table-wrap><p>On comparison of CI and SVRI there was no statistical significance between the two groups. PVRI was significantly lower in sildenafil group after induction, after weaning from CPB, and in the postoperative period [<xref ref-type="table" rid="T2">Table 2</xref>].</p><p>During the period of weaning from CPB, the number of patients who required dobutamine infusion was lower in S group (<italic>P</italic> &#x0003c; 0.01), whereas the number of patients requiring norepinephrine infusion was not significantly different between the two groups (<italic>P</italic> &#x0003c; 0.23; <xref ref-type="table" rid="T3">Table 3</xref>]. Postoperative parameters like ventilation time and postoperative ICU (intensive care unit) stay time was significantly lower in sildenafil group (<italic>P</italic> = 0.011) as compared with control group [<xref ref-type="table" rid="T3">Table 3</xref>]. During study, there was one mortality due to low output noted in control group on second postoperative day.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Perioperative parameters during mitral valve replacement surgery in sildenafil and control group of patients (<italic>N</italic>=20)</p></caption><graphic xlink:href="IJPharm-46-281-g003"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>In this prospective double-blind randomized controlled study, oral sildenafil 25 mg three times over 24 h before surgery produced significant pulmonary vasodilatation without any significant systemic effects. Sildenafil has a favorable effect like lowering pulmonary vascular resistance after induction of anesthesia that extended into postoperative period. SPAP, MPAP, and PVRI were significantly lower in sildenafil group (<italic>P</italic> &#x0003c; 0.0001) as compared with controlled group during the intraoperative period as well as in postoperative period.</p><p>Cardiac surgery in patients with valvular heart disease with severe PAH is often complicated with RV failure with an adverse consequence on its prognosis.[<xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>] Right ventricle is susceptible to ischemic injury, as CPB exacerbates PAH,[<xref rid="ref14" ref-type="bibr">14</xref>] This necessitates perioperative strategy to manage PAH and RV dysfunction. This goal should be achieved without compromising systemic blood pressure and coronary perfusion.[<xref rid="ref15" ref-type="bibr">15</xref>]</p><p>The final messenger for vascular smooth muscle relaxation, cGMP, is metabolized by PDE5.[<xref rid="ref16" ref-type="bibr">16</xref>] Among the various phosphodiesterase, PDE5 is the predominant type in the normal pulmonary vasculature that may be upregulated after CPB.[<xref rid="ref17" ref-type="bibr">17</xref>] The inhibition of PDE5 is therefore a logical step to increase the bioavailability of cGMP and support endogenous vasodilation in patient with PAH. PDE5 is selectively inhibited by sildenafil, vardenafil, and tadalafil and less selectively by zaprinast and dipyridamole.[<xref rid="ref8" ref-type="bibr">8</xref>]</p><p>Oral sildenafil is widely used in treatment of patients with erectile dysfunction and shows an excellent cardiovascular safety profile.[<xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref19" ref-type="bibr">19</xref>] It is emerging as an effective and safe pulmonary vasodilator in primary pulmonary hypertension[<xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref>] as well as secondary pulmonary hypertension.[<xref rid="ref22" ref-type="bibr">22</xref><xref rid="ref23" ref-type="bibr">23</xref>] PDE5 is abundant in lung tissue; hence sildenafil selectively inhibits it and preferentially dilates pulmonary vascular beds.[<xref rid="ref16" ref-type="bibr">16</xref>] Oral sildenafil selectively reduced pulmonary hypertension without any adverse systemic effects.[<xref rid="ref24" ref-type="bibr">24</xref>]</p><p>In the present study, 25 mg of oral sildenafil was administered three times a day for 24 h with the last dose administered 3 h prior to surgery. Wilkens <italic>et al</italic>.,[<xref rid="ref21" ref-type="bibr">21</xref>] demonstrated that the maximal hemodynamic effects of sildenafil on pulmonary circulation could be achieved with a dose as low as 25 mg. We used three doses over 24 h to reduce pulmonary hypertension and improve RV function prior to surgery. Sildenafil has a half-life of about 4 h; it is rapidly absorbed via the stomach and its plasma levels peaks within 30-120 min after ingestion.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref18" ref-type="bibr">18</xref>] Considering these facts, the last dose of sildenafil was administered 3 h prior to surgery.</p><p>In this study, SPAP, MPAP, and PVRI were significantly lower (<italic>P</italic> &#x0003c; 0.0001) after induction of anesthesia, after weaning from CPB, and in immediate postoperative period in sildenafil group as compared with control group. But MAP, PCWP and CI, and SVRI were no significantly differing between two groups. During weaning from CPB, we started GTN infusion and dobutamine infusion in all patients. Inotropes, dobutamine infusion (5-10 &#x003bc;g/kg/min) continued when MAP was lower than 60 mmHg and also norepinephrine infusion (0.05-0.1 &#x003bc;g/kg/min) was added whenever required. In sildenafil group, six (30%) patients required dobutamine infusion, of these two (33.3%) patients required norepinephrine infusion. In the control group, 14 patients required dobutamine infusion and of these five patients required norepinephrine infusion. Sildenafil group had fewer requirements of inotropes than control group. Ventilation time and postoperative recovery room times were significantly lower (<italic>P</italic> = 0.001) in sildenafil group as compared with control group. Mortality occurred on the second postoperative day due to low output.</p><p>In conclusion, preoperative oral sildenafil reduces pulmonary artery pressure in the perioperative period in patients with severe pulmonary hypertension secondary to mitral valve disease undergoing mitral valve replacement. Because of the predominant selective activity of sildenafil in management of pulmonary hypertension and improvement of RV function without compromising the systemic blood pressure, the use of this drug in cardiac surgical patients should be considered. Elaborate studies of oral sildenafil in secondary PAH in larger populations will help validate the results of this study.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge Dr. Sunil Trivedi (Chief Research Officer), Mr. Paresh Dhamecha for statistical analysis, and Ms. Himani Pandya and Ms. Nrupa Kumthekar for assistance.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict Interest:</bold> No</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simonneau</surname><given-names>G</given-names></name><name><surname>Gali&#x000e8;</surname><given-names>N</given-names></name><name><surname>Rubin</surname><given-names>LJ</given-names></name><name><surname>Langleben</surname><given-names>D</given-names></name><name><surname>Seeger</surname><given-names>W</given-names></name><name><surname>Domenighetti</surname><given-names>G</given-names></name><etal/></person-group><article-title>Clinical classification of pulmonary hypertension</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>43</volume><fpage>5</fpage><lpage>12S</lpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>WE</given-names></name><name><surname>Ochoa</surname><given-names>LL</given-names></name><name><surname>Richardson</surname><given-names>GW</given-names></name><name><surname>Trulock</surname><given-names>EP</given-names></name></person-group><article-title>Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome</article-title><source>J Heart Lung Transplant</source><year>1996</year><volume>15</volume><fpage>100</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8820089</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Alonzo</surname><given-names>GE</given-names></name><name><surname>Barst</surname><given-names>RJ</given-names></name><name><surname>Ayres</surname><given-names>SM</given-names></name><name><surname>Bergofsky</surname><given-names>EH</given-names></name><name><surname>Brundage</surname><given-names>BH</given-names></name><name><surname>Detre</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Survival in patients with primary pulmonary hypertension: Results from a national prospective registry</article-title><source>Ann Intern Med</source><year>1991</year><volume>115</volume><fpage>343</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1863023</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archer</surname><given-names>S</given-names></name><name><surname>Rich</surname><given-names>S</given-names></name></person-group><article-title>Primary pulmonary hypertension: A vascular biology and translational research &#x0201c;Work in progress&#x0201d;</article-title><source>Circulation</source><year>2000</year><volume>102</volume><fpage>2781</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">11094047</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khazin</surname><given-names>V</given-names></name><name><surname>Kaufman</surname><given-names>Y</given-names></name><name><surname>Zabeeda</surname><given-names>D</given-names></name><name><surname>Medalion</surname><given-names>B</given-names></name><name><surname>Sasson</surname><given-names>L</given-names></name><name><surname>Schachner</surname><given-names>A</given-names></name><etal/></person-group><article-title>Milrinone and nitric oxide: Combined effect on pulmonary artery pressures after cardiopulmonary bypass in children</article-title><source>J Cardiothorac Vasc Anesth</source><year>2004</year><volume>18</volume><fpage>156</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15073704</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thelitz</surname><given-names>S</given-names></name><name><surname>Oishi</surname><given-names>P</given-names></name><name><surname>Sanchez</surname><given-names>LS</given-names></name><name><surname>Bekker</surname><given-names>JM</given-names></name><name><surname>Ovadia</surname><given-names>B</given-names></name><name><surname>Johengen</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs</article-title><source>Pediatr Crit Care Med</source><year>2004</year><volume>5</volume><fpage>234</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15115560</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oishi</surname><given-names>P</given-names></name><name><surname>Grobe</surname><given-names>A</given-names></name><name><surname>Benavidez</surname><given-names>E</given-names></name><name><surname>Ovadia</surname><given-names>B</given-names></name><name><surname>Harmon</surname><given-names>C</given-names></name><name><surname>Ross</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Inhaled nitric oxide induced NOS inhibition and rebound pulmonary hypertension: A role for superoxide and peroxynitrite in the intact lamb</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2006</year><volume>290</volume><fpage>L359</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">16258003</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raja</surname><given-names>SG</given-names></name><name><surname>Nayak</surname><given-names>SH</given-names></name></person-group><article-title>Sildenafil: Emerging cardiovascular indications</article-title><source>Ann Thorac Surg</source><year>2004</year><volume>78</volume><fpage>1496</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">15464535</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>S</given-names></name><name><surname>Wilkinson</surname><given-names>J</given-names></name><name><surname>Gatzoulis</surname><given-names>MA</given-names></name></person-group><article-title>Sildenafil in primary pulmonary hypertension</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>1342</fpage><pub-id pub-id-type="pmid">11183578</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghofrani</surname><given-names>HA</given-names></name><name><surname>Olschewski</surname><given-names>H</given-names></name><name><surname>Seeger</surname><given-names>W</given-names></name><name><surname>Grimminger</surname><given-names>F</given-names></name></person-group><article-title>Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure</article-title><source>Pneumologie</source><year>2002</year><volume>56</volume><fpage>665</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">12442206</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trachte</surname><given-names>AL</given-names></name><name><surname>Lobato</surname><given-names>EB</given-names></name><name><surname>Urdaneta</surname><given-names>F</given-names></name><name><surname>Hess</surname><given-names>PJ</given-names></name><name><surname>Klodell</surname><given-names>CT</given-names></name><name><surname>Martin</surname><given-names>TD</given-names></name><etal/></person-group><article-title>Oral sildenafil reduces pulmonary hypertension after cardiac surgery</article-title><source>Ann Thorac Surg</source><year>2005</year><volume>79</volume><fpage>194</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15620942</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>C</given-names></name><name><surname>Hancock</surname><given-names>BW</given-names></name></person-group><article-title>Extreme pulmonary hypertension caused by mitral valve disease: Natural history and results of surgery</article-title><source>Br Heart J</source><year>1975</year><volume>37</volume><fpage>74</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1111561</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malouf</surname><given-names>JF</given-names></name><name><surname>Enriquez-Sarano</surname><given-names>M</given-names></name><name><surname>Pellikka</surname><given-names>PA</given-names></name><name><surname>Oh</surname><given-names>JK</given-names></name><name><surname>Bailey</surname><given-names>KR</given-names></name><name><surname>Chandrasekaran</surname><given-names>K</given-names></name><etal/></person-group><article-title>Severe pulmonary hypertension in patients with severe aortic valve stenosis: Clinical profile and prognostic implications</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>40</volume><fpage>789</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">12204512</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangano</surname><given-names>DT</given-names></name></person-group><article-title>Biventricular function after myocardial revascularization in humans: deterioration and recovery patterns during the first 24 hours</article-title><source>Anesthesiology</source><year>1985</year><volume>62</volume><fpage>571</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3873186</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvin</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>Acute right heart failure: Pathophysiology, recognition, and pharmacological management</article-title><source>J Cardiothorac Vasc Anesth</source><year>1991</year><volume>5</volume><fpage>507</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">1932658</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Tenor</surname><given-names>H</given-names></name><name><surname>Dent</surname><given-names>G</given-names></name><name><surname>Schudt</surname><given-names>C</given-names></name><name><surname>Nakashima</surname><given-names>M</given-names></name><name><surname>Magnussen</surname><given-names>H</given-names></name></person-group><article-title>Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors</article-title><source>Am J Physiol</source><year>1994</year><volume>266</volume><fpage>536</fpage><lpage>43</lpage></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giad</surname><given-names>A</given-names></name><name><surname>Saleh</surname><given-names>D</given-names></name></person-group><article-title>Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension</article-title><source>N Engl J Med</source><year>1995</year><volume>333</volume><fpage>214</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">7540722</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boolell</surname><given-names>M</given-names></name><name><surname>Allen</surname><given-names>MJ</given-names></name><name><surname>Ballard</surname><given-names>SA</given-names></name><name><surname>Gepi-Attee</surname><given-names>S</given-names></name><name><surname>Muirhead</surname><given-names>GJ</given-names></name><name><surname>Naylor</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction</article-title><source>Int J Impot Res</source><year>1996</year><volume>8</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">8858389</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloner</surname><given-names>RA</given-names></name><name><surname>Zusman</surname><given-names>RM</given-names></name></person-group><article-title>Cardiovascular effects of sildenafil citrate and recommendations for its use</article-title><source>Am J Cardiol</source><year>1999</year><volume>84</volume><fpage>11N</fpage><lpage>7</lpage></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sastry</surname><given-names>BK</given-names></name><name><surname>Narasimhan</surname><given-names>C</given-names></name><name><surname>Reddy</surname><given-names>NK</given-names></name><name><surname>Raju</surname><given-names>BS</given-names></name></person-group><article-title>Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>43</volume><fpage>1149</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15063421</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkens</surname><given-names>H</given-names></name><name><surname>Guth</surname><given-names>A</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>J</given-names></name><name><surname>Forestier</surname><given-names>N</given-names></name><name><surname>Cremers</surname><given-names>B</given-names></name><name><surname>Hennen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effects of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension</article-title><source>Circulation</source><year>2001</year><volume>104</volume><fpage>1218</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">11551870</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cubillos-Garz&#x000f3;n</surname><given-names>LA</given-names></name><name><surname>Casas</surname><given-names>JP</given-names></name><name><surname>Morillo</surname><given-names>CA</given-names></name></person-group><article-title>Sildenafil in secondary pulmonary hypertension</article-title><source>Int J Cardiol</source><year>2003</year><volume>89</volume><fpage>101</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">12727014</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghofrani</surname><given-names>HA</given-names></name><name><surname>Wiedemann</surname><given-names>R</given-names></name><name><surname>Rose</surname><given-names>F</given-names></name><name><surname>Schermuly</surname><given-names>RT</given-names></name><name><surname>Olschewski</surname><given-names>H</given-names></name><name><surname>Weissmann</surname><given-names>N</given-names></name><etal/></person-group><article-title>Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomized controlled trial</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>895</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">12354470</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schermuly</surname><given-names>RT</given-names></name><name><surname>Kreisselmeier</surname><given-names>KP</given-names></name><name><surname>Ghofrani</surname><given-names>HA</given-names></name><name><surname>Yilmaz</surname><given-names>H</given-names></name><name><surname>Butrous</surname><given-names>G</given-names></name><name><surname>Ermert</surname><given-names>L</given-names></name><etal/></person-group><article-title>Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats</article-title><source>Am J Respir Crit Care Med</source><year>2004</year><volume>169</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">12958054</pub-id></element-citation></ref></ref-list></back></article>